Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis.

The global burden of tuberculosis (TB) is still large. The increasing incidence of drug-resistant, multidrug-resistant (MDR) (resistant to at least rifampicin and isoniazid), and extensively drug-resistant (XDR) (additionally resistant to a fluoroquinolone and kanamycin/amikacin/capreomycin) strains of Mycobacterium tuberculosis and the association of active disease with human immunodeficiency virus coinfection pose a major threat to TB control efforts. The rapid detection of M. tuberculosis strains and drug susceptibility testing (DST) for anti-TB drugs ensure the provision of effective treatment. Rapid molecular diagnostic and DST methods have been developed recently. Treatment of drug-susceptible TB is effective in ≥95% of disease cases; however, supervised therapy for ≥6 months is challenging. Non-adherence to treatment often results in the evolution of drug-resistant strains of M. tuberculosis due to mutations in the genes encoding drug targets. Sequential accumulation of mutations results in the evolution of MDR and XDR strains of M. tuberculosis. Effective treatment of MDR-TB involves therapy with 5-7 less effective, expensive, and toxic second-line and third-line drugs for ≥24 months and is difficult in most developing countries. XDR-TB is generally an untreatable disease in developing countries. Some currently existing drugs and several new drugs with novel modes of action are in various stages of development to shorten the treatment duration of drug-susceptible TB and to improve the outcome of MDR-TB and XDR-TB.

[1]  A. Lee,et al.  Molecular diagnostic methods for the detection of Mycobacterium tuberculosis resistance: the potential of high-resolution melting analysis , 2012, Expert review of anti-infective therapy.

[2]  Marcos Burgos,et al.  Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients , 2012, PLoS medicine.

[3]  Suhail Ahmad,et al.  Performance comparison of four methods for detecting multidrug-resistant Mycobacterium tuberculosis strains. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[4]  L. Amaral,et al.  Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections. , 2012, International journal of antimicrobial agents.

[5]  J. Palomino,et al.  Is repositioning of drugs a viable alternative in the treatment of tuberculosis? , 2013, The Journal of antimicrobial chemotherapy.

[6]  Stewart T. Cole,et al.  High Content Screening Identifies Decaprenyl-Phosphoribose 2′ Epimerase as a Target for Intracellular Antimycobacterial Inhibitors , 2009, PLoS pathogens.

[7]  N. Doi,et al.  Characteristic Resistance Mechanism of Mycobacterium tuberculosis to DC-159a, a New Respiratory Quinolone , 2011, Antimicrobial Agents and Chemotherapy.

[8]  Suhail Ahmad,et al.  Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis. , 2009, Respiratory medicine.

[9]  Ying Zhang,et al.  Pyrazinamide Inhibits Trans-Translation in Mycobacterium tuberculosis , 2011, Science.

[10]  V. Ausina,et al.  GenoType MTBDRsl for Molecular Detection of Second-Line-Drug and Ethambutol Resistance in Mycobacterium tuberculosis Strains and Clinical Samples , 2011, Journal of Clinical Microbiology.

[11]  K. Andries,et al.  Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells. , 2010, Tuberculosis.

[12]  A. Diacon,et al.  14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial , 2012, The Lancet.

[13]  A. Telenti,et al.  The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol , 1997, Nature Medicine.

[14]  J. Musser,et al.  Characterization of rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographic localities , 1996, Antimicrobial agents and chemotherapy.

[15]  A. Van Deun,et al.  Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. , 2010, American journal of respiratory and critical care medicine.

[16]  C. Wells Global Impact of Multidrug-Resistant Pulmonary Tuberculosis Among HIV-Infected and Other Immunocompromised Hosts: Epidemiology, Diagnosis, and Strategies for Management , 2010, Current infectious disease reports.

[17]  E. Mokaddas,et al.  Frequency of embB codon 306 mutations in ethambutol-susceptible and -resistant clinical Mycobacterium tuberculosis isolates in Kuwait. , 2007, Tuberculosis.

[18]  E. Kurbatova,et al.  Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study , 2012, The Lancet.

[19]  H. Schünemann,et al.  Use of Anti-Retroviral Therapy in Tuberculosis Patients on Second-Line Anti-TB Regimens: A Systematic Review , 2012, PloS one.

[20]  P. Donald,et al.  Paediatric use of second-line anti-tuberculosis agents: a review. , 2012, Tuberculosis.

[21]  K. Andries,et al.  Sterilizing Activities of Novel Combinations Lacking First- and Second-Line Drugs in a Murine Model of Tuberculosis , 2012, Antimicrobial Agents and Chemotherapy.

[22]  H. Boshoff,et al.  Nitroimidazoles for the treatment of TB: past, present and future. , 2011, Future medicinal chemistry.

[23]  J. Palomino,et al.  Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. , 2011, The Journal of antimicrobial chemotherapy.

[24]  M. Jiménez-Corona,et al.  Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes , 2012, Thorax.

[25]  K. Steingart,et al.  Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[26]  M. Pai,et al.  Initial Drug Resistance and Tuberculosis Treatment Outcomes: Systematic Review and Meta-analysis , 2008, Annals of Internal Medicine.

[27]  Stefan Niemann,et al.  Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes , 2011 .

[28]  C. Nacy,et al.  SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro. , 2012, The Journal of antimicrobial chemotherapy.

[29]  Ping Chen,et al.  Identification of SQ609 as a lead compound from a library of dipiperidines. , 2011, Bioorganic & medicinal chemistry letters.

[30]  D. Mitchison,et al.  The chemotherapy of tuberculosis: past, present and future. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[31]  J. Grosset,et al.  Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. , 2009, American journal of respiratory and critical care medicine.

[32]  H. Rieder Fourth-generation fluoroquinolones in tuberculosis , 2009, The Lancet.

[33]  Markus Sköld,et al.  Tuberculosis and HIV Co-Infection , 2012, PLoS pathogens.

[34]  K. Shaw,et al.  The oxazolidinones: past, present, and future , 2011, Annals of the New York Academy of Sciences.

[35]  S. Cole,et al.  The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis , 1992, Nature.

[36]  Yanlin Zhao,et al.  The Beginning of the rpoB Gene in Addition to the Rifampin Resistance Determination Region Might Be Needed for Identifying Rifampin/Rifabutin Cross-Resistance in Multidrug-Resistant Mycobacterium tuberculosis Isolates from Southern China , 2011, Journal of Clinical Microbiology.

[37]  M. Murray,et al.  Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  A. Zaha,et al.  Streptomycin Resistance and Lineage-Specific Polymorphisms in Mycobacterium tuberculosis gidB Gene , 2011, Journal of Clinical Microbiology.

[39]  J. Fitzgerald,et al.  Treatment Outcomes of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis , 2009, PloS one.

[40]  Y. Balabanova,et al.  Diagnosis of tuberculosis and drug resistance: what can new tools bring us? , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[41]  C. Nacy,et al.  Chemical modification of capuramycins to enhance antibacterial activity. , 2011, The Journal of antimicrobial chemotherapy.

[42]  B. Hedt-Gauthier,et al.  Outcomes of Multidrug-Resistant Tuberculosis Treatment with Early Initiation of Antiretroviral Therapy for HIV Co-Infected Patients in Lesotho , 2012, PloS one.

[43]  J. Grosset,et al.  Activity of the Fluoroquinolone DC-159a in the Initial and Continuation Phases of Treatment of Murine Tuberculosis , 2011, Antimicrobial Agents and Chemotherapy.

[44]  D. Mitchison,et al.  The chemotherapy of tuberculosis: past, present and future [State of the art]. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[45]  J. Palomino,et al.  Current developments and future perspectives for TB diagnostics. , 2012, Future microbiology.

[46]  P. V. van Helden,et al.  Genotype MTBDRsl line probe assay shortens time to diagnosis of extensively drug-resistant tuberculosis in a high-throughput diagnostic laboratory. , 2012, American journal of respiratory and critical care medicine.

[47]  A. Telenti,et al.  Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis , 1993, The Lancet.

[48]  C. Nacy,et al.  Drug Therapy of Experimental Tuberculosis (TB): Improved Outcome by Combining SQ109, a New Diamine Antibiotic, with Existing TB Drugs , 2007, Antimicrobial Agents and Chemotherapy.

[49]  J. Furin The clinical management of drug-resistant tuberculosis , 2007, Current opinion in pulmonary medicine.

[50]  Evan W. Orenstein,et al.  Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. , 2009, The Lancet. Infectious diseases.

[51]  L. Gakuu Treatment of tuberculosis of the hip , 1996 .

[52]  K. Andries,et al.  Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance , 2012, Antimicrobial Agents and Chemotherapy.

[53]  A. Matsuda,et al.  Structure-activity relationship of truncated analogs of caprazamycins as potential anti-tuberculosis agents. , 2008, Bioorganic & medicinal chemistry.

[54]  Stephen D. Bentley,et al.  Microevolution of extensively drug-resistant tuberculosis in Russia. , 2012, Genome research.

[55]  S. Cole,et al.  In Vitro Combination Studies of Benzothiazinone Lead Compound BTZ043 against Mycobacterium tuberculosis , 2012, Antimicrobial Agents and Chemotherapy.

[56]  Y. Hwang,et al.  Clinical efficacy of direct DNA sequencing analysis on sputum specimens for early detection of drug-resistant Mycobacterium tuberculosis in a clinical setting. , 2010, Chest.

[57]  D. Menzies,et al.  Clinical outcomes of pyrazinamide-monoresistant Mycobacterium tuberculosis in Quebec. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[58]  W. Bishai,et al.  New drugs for the treatment of tuberculosis: hope and reality. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[59]  P. V. van Helden,et al.  gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. , 2012, The Journal of antimicrobial chemotherapy.

[60]  Y. Balabanova,et al.  Performance of the GenoType® MTBDRPlus assay in routine settings: a multicenter study , 2011, European Journal of Clinical Microbiology & Infectious Diseases.

[61]  Alimuddin Zumla,et al.  Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. , 2010, The Lancet. Infectious diseases.

[62]  R. Garfein,et al.  Evaluation of Genetic Mutations Associated with Mycobacterium tuberculosis Resistance to Amikacin, Kanamycin and Capreomycin: A Systematic Review , 2012, PloS one.

[63]  N. Ford,et al.  Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[64]  S. Rüsch-Gerdes,et al.  Direct Drug Susceptibility Testing of Mycobacterium tuberculosis for Rapid Detection of Multidrug Resistance Using the Bactec MGIT 960 System: a Multicenter Study , 2011, Journal of Clinical Microbiology.

[65]  A. Harries,et al.  The looming epidemic of diabetes-associated tuberculosis: learning lessons from HIV-associated tuberculosis. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[66]  F. Drobniewski,et al.  Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate. , 2013, The Journal of antimicrobial chemotherapy.

[67]  C. Daley,et al.  Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[68]  Suhail Ahmad,et al.  Contribution of AGC to ACC and other mutations at codon 315 of the katG gene in isoniazid-resistant Mycobacterium tuberculosis isolates from the Middle East. , 2004, International journal of antimicrobial agents.

[69]  K. Kam,et al.  Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance , 2009, The Lancet.

[70]  Sadhna Sharma,et al.  Phenothiazines as anti-tubercular agents: mechanistic insights and clinical implications , 2011, Expert opinion on investigational drugs.

[71]  Ying Zhang,et al.  Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus , 1996, Nature Medicine.

[72]  M. Heo,et al.  Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[73]  E. Mokaddas,et al.  Secular trends in susceptibility patterns of Mycobacterium tuberculosis isolates in Kuwait, 1996-2005. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[74]  Fake Li,et al.  Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. , 2012, The Journal of infection.

[75]  F. Portaels,et al.  Rapid culture-based methods for drug-resistance detection in Mycobacterium tuberculosis. , 2008, Journal of microbiological methods.

[76]  K. Dooley,et al.  World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? , 2013, The Journal of infectious diseases.

[77]  R. Kempker,et al.  Adjunctive surgery improves treatment outcomes among patients with multidrug-resistant and extensively drug-resistant tuberculosis. , 2012, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[78]  D. Moore,et al.  Alternative methods of diagnosing drug resistance--what can they do for me? , 2011, The Journal of infectious diseases.

[79]  A. Benedetti,et al.  Standardized Treatment of Active Tuberculosis in Patients with Previous Treatment and/or with Mono-resistance to Isoniazid: A Systematic Review and Meta-analysis , 2009, PLoS medicine.

[80]  Suhail Ahmad New approaches in the diagnosis and treatment of latent tuberculosis infection , 2010, Respiratory research.

[81]  K. Andries,et al.  Sterilizing Activity of Novel TMC207- and PA-824-Containing Regimens in a Murine Model of Tuberculosis , 2011, Antimicrobial Agents and Chemotherapy.

[82]  Charles L Daley,et al.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. , 2003, American journal of respiratory and critical care medicine.

[83]  Eduardo Gotuzzo,et al.  Rapid molecular detection of tuberculosis and rifampin resistance. , 2010, The New England journal of medicine.

[84]  Gee Young Suh,et al.  Delamanid for multidrug-resistant pulmonary tuberculosis. , 2012, The New England journal of medicine.

[85]  Stewart T. Cole,et al.  Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis , 2009, Science.

[86]  G. Kahlmeter,et al.  Wild-Type MIC Distributions for Aminoglycoside and Cyclic Polypeptide Antibiotics Used for Treatment of Mycobacterium tuberculosis Infections , 2010, Journal of Clinical Microbiology.